2026-05-30T03:54:43Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/228542026-02-03T12:01:11Zcom_10630_2254col_10630_37959

Study of the antitumor potential of stauprimide in breast cancer Carrillo Fernández, Paloma Téllez Quijorna, Clara Bernal, Manuel Rodríguez-Quesada, Ana María Medina-Torres, Miguel Ángel Martínez-Póveda, Beatriz Amparo Cáncer - Congresos Contribución a Congreso (póster) Stauprimide, a semi-synthetic derivative of staurosporine, was characterized in 2009 as a potent differentiation-enhancing compound in embryonic stem cells [1]. Although it was first thought that this compound could maintain the properties of staurosporine as a non-selective inhibitor of protein kinases (especially potent in inhibiting tyrosine kinases), it was found that its potential as an inhibitor of these proteins was not particularly remarkable, ruling out this as its main mechanism of action for the differentiation-enhancing effect. However, a clear effect of stauprimide on embryonic stem cells was identified as an inhibitor of CMYC expression, a key factor in the maintenance of stem cell pluripotency [1]. Given the involvement of CMYC in cancer development, and the effect of stauprimide inhibiting its expression, this compound was proposed as a possible antitumor drug in the treatment of renal cancer [2]. In this work we have studied the in vitro antitumor effect of stauprimide in the context of breast cancer, exploring also the possible mechanisms of action by which stauprimide exerts its effects. The detected activity of this compound on the human adenocarcinoma model used in our studies suggests its potential usefulness in antitumor pharmacological strategies. 2021-09-20T09:44:35Z 2021-09-20T09:44:35Z 2021 2021 conference output https://hdl.handle.net/10630/22854 eng 43 Congreso Anual de la Sociedad Española de Bioquímica y Biología Molecular Barcelona Julio 2021 open access